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Nuclear RIPK3 and MLKL contribute to cytosolic
necrosome formation and necroptosis
Kathrin Weber 1,2, Ria Roelandt1,2, Inge Bruggeman1,2, Yann Estornes1,2,3 & Peter Vandenabeele 1,2
Necroptotic signaling converges in the assembly of a cytosolic signaling platform, the
necrosome, with the activation of its downstream effector, MLKL. RIPK1 and RIPK3, key
components of the necrosome, act as signaling intermediates for the activation of MLKL. We
report that RIPK3 and MLKL continuously shuttle between the nucleus and the cytoplasm,
whereas RIPK1 is constitutively present in both compartments. During TNF-induced
necroptosis, nuclear RIPK1 becomes ubiquitinated, after which nuclear MLKL becomes
phosphorylated and oligomerized. Pharmacological inhibition of the nuclear export machinery
leads to retention of RIPK3 and MLKL in the nucleus, prevents the nucleation of cytosolic
RIPK3/MLKL oligomerization, and reduces cell death. Our results suggest that passage of
necroptotic signaling components through the nucleus is a mechanism for regulating cyto-
solic necrosome formation and consequently necroptotic cell death.
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Programmed necrosis (necroptosis) is a form of non-apoptotic cell death playing important roles in manyinflammatory conditions and related diseases1. The most
intensively studied model for programmed necrosis is the
necroptotic pathway’s response to tumor necrosis factor (TNF).
Ligand association of TNF with its cognate receptor TNF receptor
(TNFR)-1 results in the formation of a membrane-associated
TNFR-1 signaling complex named complex I. Within this com-
plex, ubiquitinated receptor interacting protein 1 (RIPK1) pro-
motes activation of the NF-κB pathway. De-ubiquitination of
RIPK1 leads to the assembly of a cytosolic death complex
(complex IIb), which promotes apoptotic cell death2 and contains
active caspase-8, FAS-associated via death domain protein
(FADD), RIPK1 and RIPK3. However, blocking caspase-8 activity
by genetic ablation, chemical inhibitors, or viral caspase inhibitors
leads to the generation of an alternative cytosolic complex IIc, the
necrosome, which induces necroptotic cell death3–5. Mechan-
istically, the effector mixed-lineage kinase domain like (MLKL) is
recruited to the necrosome, followed by its phosphorylation by
RIPK3. This induces a conformational change in MLKL and
exposes its N-terminal death effector domain (4 helical bundle
domain, 4HBD). Subsequently, MLKL translocates to the plasma
membrane and causes its permeabilization6–10.
The serine/threonine kinases RIPK1 and RIPK3 are the core
components of the necroptotic signaling platform. The two pro-
teins associate with each other through their RIP homotypic
interaction motif (RHIM) domains into heteromeric RIPK1:
RIPK3 complexes, and further polymerize into filamentous β-
amyloid structures11. RIPK1 might phosphorylate RIPK3 within
the necrosome, promoting the activation of RIPK3 kinase3, but
there is no direct experimental proof yet. The RIPK3 activating
function of RIPK1 can be replaced in certain circumstances by
other RHIM-containing proteins, such as the TLR3/TLR4 adaptor
TRIF and the DNA sensor DAI/ZBP12–14. In contrast to these
heterodimeric activation models, recent findings revealed that
chemically induced RIPK3 homo-oligomerization is sufficient to
induce necroptosis15–17. In that situation, RIPK3 kinase activity is
activated by proximity within RIPK3 oligomers. Moreover, the
intracellular localization of the necrosome is also still unclear. The
necrosome was described as present in detergent-insoluble frac-
tions (NP-40/Triton X-100) as amyloid-like aggregates11, 18,
whereas other groups have successfully immunoprecipitated
complexes containing RIPK1:RIPK3 from detergent-soluble
fractions19. Thus, the necroptotic death complex might initially
form in the cytosol and subsequently migrate to the detergent-
insoluble cellular compartments, such as the endoplasmic reti-
culum (ER), Golgi, and mitochondria-associated membranes7, 20.
In addition, all three necroptotic key players (RIPK1, RIPK3, and
MLKL) were recently found to translocate to the nucleus early in
necroptosis and NLRP3 inflammasome activation21. However,
the physiological relevance of this nuclear localization remains
unknown.
Here we show that RIPK3 and MLKL are constitutive nucleo-
cytoplasmic shuttling proteins. Following necroptosis induction,
RIPK3 and MLKL are activated in the nucleus, and after their
cooperative nuclear export, they contribute to cytosolic necro-
some formation. Consequently, the export of RIPK3 and MLKL
from the nucleus to the cytosol is important for necroptotic cell
death.
Results
Nuclear RIPK3 is involved in necroptosis. RIPK3 acts as a
nucleo-cytoplasmic shuttling protein22. We confirmed that in the
steady state, GFP-RIPK3 was diffusely present predominantly in
the cytoplasm, and that inhibition of nuclear export by
Leptomycin B (LMB) led to retention of 44± 3.4% of total GFP-
RIPK3 in the nucleus (Fig. 1a, f). Thus, RIPK3 continuously
shuttles between the cytoplasm and the nucleus.
As RIPK3 is a key mediator of necroptotic cell death, we
reasoned that nuclear-cytoplasmic shuttling of RIPK3 could affect
necroptosis. When FADD-deficient Jurkat cells are treated with
TNF, they undergo RIPK3-dependent necroptosis3, 23. In
agreement, we showed that 8 h of TNF treatment resulted in
the death of FADD-deficient Jurkat cells (46± 3.7%). This cell
death was inhibited by an inhibitor of RIPK1 kinase activity (Nec-
1), but not by a general caspase inhibitor (zVAD-fmk)
(Supplementary Fig. 1, Fig. 1b). Inhibition of nuclear export by
LMB reduced necroptosis induction from 46± 3.7% to 22± 1.7%
(at 8 h), and this inhibitory effect was maintained over time (from
69± 5.1% to 38± 2.4% at 12 h) (Fig. 1b). We validated these
results by LMB treatment in another classical necroptotic model
system in which mouse embryonic fibroblasts (MEF) are treated
with a combination of TNF, Tak1 inhibitor (Taki) and zVAD-
fmk24, 25. Addition of LMB reduced necroptosis in MEF cells to
an extent resembling that observed in FADD-deficient Jurkat cells
(Fig. 1b, Supplementary Fig. 2). To validate the role of nuclear
compartmentalization in necroptotic signaling, we inhibited
nuclear import by a non-hydrolyzable GTP analog (GppNHp).
Nuclear import requires the hydrolysis of GTP by Ran, which
recycles the import carriers (importins) in the cytosol in order to
initiate new rounds of cargo import26–28. GppNHp reduced not
only TNF-induced necroptosis in FADD-deficient Jurkat cells to
24± 1.7% at 8 h (Fig. 1b), but also necroptosis induced by TNF,
BV6 smac mimetic (which depletes cIAPs29), and zVAD-fmk
(TBZ) in GFP-RIPK3-expressing HeLa cells from 50± 1.9% to 35
± 2.8% (Fig. 1c). However, GppNHp did not inhibit nuclear
import of GFP-RIPK3, which accumulated in the nucleus,
recapitulating the intracellular distribution observed in the
presence of LMB (Fig. 1a). Consequently, the nuclear import
mechanism of GFP-RIPK3 is distinct from the classical Ran-
GTP-dependent nuclear import mechanism. It is likely that
GppNHp inhibits the import of a protein required for RIPK3
nuclear export.
If reduction of necroptosis by LMB/GppNHp is evoked by
interference with the nuclear passage of RIPK3, then altering
nucleo-cytoplasmic shuttling of RIPK3 should affect necroptosis
induction. A commonly used strategy to modulate nucleo-
cytoplasmic shuttling is to inactivate intrinsic nuclear export
signal (NES) or NLS sequences by point mutation of core
residues. However, sequence analysis did not reveal any
conventional NLS or NES within RIPK3. The absence of a
conventional NLS in RIPK3 is in agreement with the unaltered
nuclear import of RIPK3 in the presence of GppNHp (Fig. 1a).
Furthermore, the existence of an unconventional C-terminal NLS
sequence (aa 442–472) could not be experimentally confirmed30,
31. In agreement with an earlier report30, we confirmed that the
kinase domain of RIPK3 (aa 1–292) is imported into the nucleus,
demonstrating the dispensable role of the RIPK3 C-terminal
region in nuclear import (Supplementary Fig. 3). In order to
increase nuclear-cytoplasmic shuttling of RIPK3 we fused the
NLS sequence of Simian Vacuolating Virus (SV)40 large T
antigen, which serves as a consensus NLS sequence, to the N-
terminus of RIPK3 (NLS-RIPK3). Thus, NLS-RIPK3 is subjected
to the classical Ran-GTP nuclear import mechanism in order to
bypass any alternative TBZ-dependent import mechanisms.
When GFP-NLS-RIPK3 was expressed in HeLa cells, in which
endogenous RIPK3 expression is silenced by promotor methyla-
tion32, it was detected in a diffuse pattern throughout the cell, and
66± 8.6% of total NLS–RIPK3 was in the nucleus (Fig. 1d, f). In
the presence of LMB, 90± 3% of the entire cellular pool of
NLS–RIPK3 accumulated in the nucleus. These results indicate
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that NLS-RIPK3 recapitulated nucleo-cytoplasmic shuttling of
wild-type RIPK3 but with a more efficient import rate. Thus,
NLS–RIPK3 can be used to analyze whether increased nucleo-
cytoplasmic shuttling, and hence nuclear passage of RIPK3,
correlates with sensitization to necroptosis. Although RIPK3 and
NLS-RIPK3 were expressed at comparable levels, only NLS-
RIPK3 exerted pro-death activity (57± 2.6% cell death) at steady
state (Fig. 1e, g). Treatment with TBZ enhanced cell death from
15± 2% to 35± 1.8% when HeLa cells expressed wild-type RIPK3
but only marginally increased NLS-RIPK3-mediated cell
death, from 57± 2.5% to 67± 3.6%. Treatment of wild-type
RIPK3-expressing HeLa cells with LMB reduced both steady-state
NLS–RIPK3-induced cell death (from 58± 3.0% to 28± 1.0%)
and TBZ-induced necroptosis (from 50± 2.0% to 30± 2.8%)
(Fig. 1h). Taken together, these results suggest that passage
of RIPK3 through the nuclear compartment contributes to
TNF-induced necroptosis.
Nuclear RIPK1 is ubiquitinated during necroptosis. Following
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RIPK1:RIPK3 translocate to different cellular compartments, such
as mitochondria associated membranes, where they exert their
function7, 20. We hypothesized that RIPK3 could be imported
into the nucleus as a pre-assembled RIPK1:RIPK3 complex. If
that was true, interference with the RIPK1:RIPK3 interaction
interface would prevent nuclear import of RIPK3. The RHIM
motif of RIPK3 represents the interface for association with
RIPK1, and tetra alanine substitution of core residues within the
RHIM domain of RIPK3 abolishes its interaction with RIPK13, 33.
Addition of LMB led to nuclear retention of 42± 4.2% of this
tetra alanine RIPK3 mutant (RIPK3-RHIMmut) in control-
treated conditions and 49± 6% in TBZ-treated conditions
(Fig. 2a, b). Apparently, the nucleo-cytoplasmic shuttling of
RIPK3-RHIMmut was not altered compared to wild-type RIPK3,
as LMB led to nuclear retention of 44± 4.2% of RIPK3-
RHIMmut and to 44± 3.4% of wild-type RIPK3 (Fig. 1a, f).
This indicates that the RHIM domain of RIPK3 (and hence
homotypic interaction with RIPK1) did not mediate the nuclear
import of RIPK3 following TNF-induced necroptosis.
RIPK1 has been reported to localize in the nucleus at steady
state34. In line with this, we found RIPK1 in nuclear fractions of
control FADD-deficient Jurkat cells (Fig. 2c), suggesting a
possible role for nuclear RIPK1 in necroptotic signaling. The
kinase activity of RIPK1 is required for TNF-induced necroptosis
to promote association with and activation of RIPK3, whereas
Nec-1, an allosteric inhibitor of RIPK1 kinase activity, efficiently
blocks necroptosis35. We found that Nec-1 restored cell viability
in RIPK3-expressing HeLa cells treated with TBZ, but it did not
affect NLS–RIPK3-induced cell death (Fig. 2d), showing that in
the latter case NLS-RIPK3-mediated cell death does not require
RIPK1 kinase activity. This suggests that mechanisms other than
RIPK1-dependent activation may be involved in NLS–RIPK3-
induced necroptosis, but not in TBZ-induced necroptosis
involving wild-type RIPK3.
RIPK1 has been reported to be regulated by ubiquitination
within the necroptotic signaling complex and consequently in the
NP-40-insoluble fraction36, 37. In agreement with these reports,
we observed modified RIPK1 as slower migrating forms on an
immunoblot of MEF cells induced to die by necroptosis by (TTZ)
TNF, Tak1 inhibitor (Taki) and zVAD-fmk treatment (Fig. 2e).
Importantly, modified RIPK1 was found almost exclusively in the
NP-40-insoluble fraction. As nuclei are largely insoluble in non-
ionic detergents like NP-40, these results imply that RIPK1 might
be ubiquitinated in the nucleus. Indeed, when RIPK1 levels were
equalized between nuclear and cytosolic fractions by loading four
times more of the nucleus-enriched fraction, we observed similar
slower migrating forms of RIPK1 in the nucleus-enriched
fractions of necroptotic FADD-deficient Jurkat cells (Fig. 2f).
This nuclear RIPK1 ubiquitination was not reduced by smac
mimetic, indicating that cIAPs are dispensable for this post-
translational modification in the nucleus (Supplementary Fig. 4a).
To determine the type of modification on nuclear RIPK1, we
performed anti-ubiquitin immunoprecipitation on nuclear frac-
tions of TNF-treated FADD-deficient Jurkat cells. RIPK1 was
recovered only after necroptosis induction, indicating its
ubiquitination (Fig. 2g). Supporting a non-degradative function
of nuclear RIPK1 ubiquitin chains, proteasome inhibition by
MG132 had no effect on the protein levels of nuclear RIPK1
(Supplementary Fig. 4b). Although inhibition of RIPK1 kinase
activity by Nec-1 has been reported to reduce RIPK1 ubiquitina-
tion36, we did not observe any dependency of RIPK1 kinase
activity on its ubiquitination in FADD-deficient Jurkat cells
(Fig. 2h). Furthermore, the presence of Nec-1 did not affect
RIPK1 levels in the nucleus (Fig. 2h). This observation contradicts
the reported necessity of RIPK1 kinase activity for its nuclear
import during necroptosis21. Addition of LMB had no effect on
nuclear RIPK1 levels, indicating that RIPK1 is not exported from
the nucleus independently of CRM1. Altogether, these results
indicate that RIPK1 is ubiquitinated in the nucleus during
necroptosis, but this ubiquitination is not affected by LMB.
RIPK3 is active in the nucleus. It has been proposed that ubi-
quitination of RIPK1 within the RIPK1:RIPK3 necrosome during
TNF signaling influences the phosphorylation and hence the
activation of RIPK336, 37. As we observed ubiquitination of RIPK1
in the nucleus (Fig. 2f), we hypothesized that a RIPK3-activating
complex is formed in the nucleus. To test this hypothesis, we first
examined whether the kinase activity of RIPK3 is required for its
nuclear import. Kinase-dead RIPK3 (D160N) exhibited a nucleo-
cytoplasmic shuttling capacity resembling that of wild-type
RIPK3, as LMB led to nuclear retention of 27± 4.3% of kinase-
dead RIPK3 compared to 44± 6.4% of wild-type RIPK3 (Figs. 3a,
b, 1f). In addition, kinase-dead RIPK3 apparently failed to
associate with its substrate, MLKL, indicating that the nuclear
import of RIPK3 is independent of its binding to MLKL (Sup-
plementary Fig. 5). Furthermore, wild-type RIPK3 was detected
as a double band only in nucleus-enriched fractions following
TBZ treatment. Also, modified NLS–RIPK3 was present only in
nuclear extracts at steady state and after TBZ treatment (Fig. 3c).
Lambda phosphatase treatment confirmed that the observed
mobility shift of NLS–RIPK3 and wild-type RIPK3 in the nuclear
fractions represented phosphorylated (i.e., active) RIPK3 (Sup-
plementary Fig. 6). Together, these results point to activation of
RIPK3 in the nucleus and prompted us to study the involvement
of MLKL in nuclear necroptotic signaling.
MLKL is a constitutive nucleo-cytoplasmic shuttling protein.
The activation of human MLKL can be inhibited by
Fig. 1 Nucleo-cytoplasmic shuttling of RIPK3 contributes to necroptosis. a Confocal images of single-optical sections of HeLa cells transiently transfected
with GFP-RIPK3. Con: control treated; LMB: LMB treated; GppNHp: GppNHp treated. The bottom panels represent merged confocal images of GFP-tagged
proteins and Hoechst (nuclear marker). Scale bars, 10 µm. b Cell death profile of FADD-deficient Jurkat cells pre-treated with LMB, GppNHp, or control
(con) followed by TNF treatment for the indicated times. The percentage of SYTOX Green+ cells was analyzed and profiles are averages± S.E.M. n
(number of independent experiments)= 5; *p< 0.01. c Cell death profile of Hela cells expressing EV or GFP-RIPK3 treated with GppNHp and TBZ and
analyzed by SYTOX Blue uptake in the GFP+ population. n= 4; *p< 0.01. d Confocal images of single-optical sections of Hela cells expressing GFP-NLS-
RIPK3. Con: control treated; LMB: treated with LMB. e Immunoblot of expression levels of GFP-RIPK3 and GFP-NLS-RIPK3 transiently expressed in HeLa
cells. Data are representative of two independent experiments. Uncropped images of immunoblots are shown in Supplementary Fig. 14. f Quantification of
the percentage of nuclear GFP-RIPK3 (20 transfected cells of two independent experiments (n= 2) analyzed) and GFP-NLS-RIPK3 (28 transfected cells of
one experiment (n= 1) analyzed) transiently expressed in HeLa cells treated or not treated with LMB. Plots indicate averages± S.E.M. g Cell death profile
of HeLa cells expressing empty vector (EV), GFP-RIPK3, or GFP-NLS-RIPK3 and treated with BV6 + zVAD-fmk (BZ), TNF, BV6 + zVAD-fmk (TBZ), or
control (con). Cells death was analyzed by SYTOX Blue uptake in the GFP+ population; n= 4; *p< 0.01. h Cell death profile of HeLa cells expressing GFP-
RIPK3 and treated with TBZ with or without LMB, or expressing GFP-NLS-RIPK3 and treated or untreated with LMB. Cell death was analyzed by SYTOX
Blue uptake in the GFP+ population; n= 3; *p= 0.01
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necrosulfonamide (NSA), which covalently bonds to MLKL Cys
86, preventing its oligomerization but not its phosphorylation19.
As MLKL is the endpoint of necroptotic signaling, NSA should
inhibit cell death induced by wild-type RIPK3 or NLS-RIPK3.
Indeed, NSA reduced to a similar extent the cell death induced by
NLS–RIPK3 (from 41± 2.1% to 3± 1.4%) or by TBZ treatment of
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Fig. 2 Nuclear RIPK1 is ubiquitinated during necroptosis. a Confocal images of single-optical sections of HeLa cells expressing GFP-RIPK3 RHIMmut treated
with control (con) or TNF, BV6 and zVAD-fmk (TBZ), with or without LMB. Scale bars: 10 µm. b Quantification of the percentage of nuclear GFP-RIPK3-
RHIMmut transiently expressed in HeLa cells and treated with control (con) or with TBZ, with or without LMB. 18–25 transfected cells of a representative
experiment of three independent experiments were analyzed. Plots indicate averages± S.E.M. c Immunoblot of intracellular distribution of RIPK1 and RIPK3
in FADD-deficient Jurkat cells comparing actual protein levels. Lactate dehydrogenase (LDH): cytosolic marker; Histone: nucleus; Flotillin: lipid rafts. Cyt:
cytosolic fraction; NE: nucleus-enriched fraction; WCE: whole-cell extract (10%). d Cell death profile of HeLa cell expressing either GFP-RIPK3 or GFP-NLS-
RIPK3 treated with TBZ with or without Nec-1 analyzed by SYTOX Blue uptake in the GFP+ population. n= 5; *p< 0.01. e Immunoblots of RIPK1 in the 1%
NP-40-soluble and -insoluble fractions of wild-type MEF cells treated with TT (TNF and TAKi) or TTZ for 4 h. f Immunoblot of RIPK1 in cytoplasmic and
nuclear fractions isolated from FADD-deficient Jurkat cells treated for the indicated times with TNF. RIPK1 levels were equalized between nuclear and
cytosolic fractions by loading four times more of the nucleus-enriched fraction. g Immunoblot of RIP1 in anti-ubiquitin immunoprecipitation of NE of FADD-
deficient Jurkat cells treated with TNF for 3 h. WNE: whole-nuclear extract. h Immunoblot of the relative amounts of cytoplasmic and nuclear RIPK1 of
FADD-deficient Jurkat cells pre-treated with Nec-1 or LMB and then with TNF (3 h). All immunoblots are representative of two or three independent
experiments. Uncropped images of immunoblots are shown in Supplementary Fig. 15
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MLKL contains a NLS sequence that is occluded in the native
conformation, and so it is found only in the cytoplasm in the
steady state. Following necroptosis induction, phosphorylation of
MLKL by RIPK3 triggers a conformational change that exposes
the NLS, facilitating MLKL import into the nucleus21. We showed
that inhibiting the nuclear export machinery with LMB led to
retention of 55± 5.6% of total cellular MLKL in the nucleus at
steady state (Fig. 3e, f). Thus, like RIPK3, MLKL is a constitutive
nucleo-cytoplasmic shuttling protein that is exported from the
nucleus in a LMB-sensitive way. In contrast to RIPK3, MLKL is
apparently imported by the classical Ran-GTP/importin-depen-
dent pathway, because inhibition of nuclear import by GppNHp
reduced LMB-induced nuclear accumulation of MLKL to 36±
5.5% (Fig. 3e, f). As GppNHp did not affect RIPK3 import
(Fig. 1a) and the constitutive association of a distinct cellular pool
of RIPK3 with MLKL (Supplementary Fig. 5; ref. 19), we speculate
that MLKL could be the GppNHp-sensitive transporting protein





















































































































































Fig. 3 RIPK3 kinase is active in the nucleus. a Confocal images of single-optical sections of Hela cells transiently expressing kinase-dead KD-RIPK3. Scale
bars: 10 µm. b Quantification of the percentage of nuclear GFP-RIPK3 D160N transiently expressed in HeLa cells treated with TBZ with or without LMB or
control-treated. 14–20 transfected cells of a representative experiment of two independent experiments were analyzed. Plots indicate averages± S.E.M.
c Immunoblot of Flag-RIPK3 in nuclear and cytosolic fractions of TBZ or control treated HeLa cells expressing EV, RIPK3 or NLS-RIPK3. Immunoblots are
representative of two independent experiments. Uncropped images of Western blots are shown in Supplementary Fig. 16. d Cell death profile of HeLa cells
transiently expressing CFP-RIPK3 or CFP-NLS-RIPK3 pre-treated with NSA or control (con) followed by treatment with TBZ; SYTOX Red uptake in the
CFP+ population was analyzed; n= 3. e Confocal images of single-optical sections of HeLa cells transiently transfected with MLKL-GFP. Left panel: con:
control treated; LMB: treated with LMB; GppNHp: treated with GppNHp; LMB + GppNHp: treated with LMB and GppNHp. Scale bars: 10 µm.
f Quantification of the percentage of nuclear MLKL-GFP transiently expressed in HeLa cells treated with control (con), LMB, GppNHp, or LMB + GppNHp.
13–24 transfected cells were analyzed of one or two independent experiments (n= 1 (GppNHp treated); n= 2 (con, LMB and GppNHp + LMB treated).
Plots indicate averages± S.E.M
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To gain further insight into whether nuclear MLKL affects
necroptosis, we employed the experimental approach we had used
for RIPK3 and fused the canonical NLS sequence of SV40 to the
C-terminus (kinase domain) of MLKL. Despite increased protein
levels, ectopic expression of wild-type or MLKL-NLS in addition
to endogenous MLKL did not enhance necroptosis compared to
control-transfected cells (Supplementary Fig. 7a, b; ref. 19). Thus,
MLKL expression levels did not correlate with necroptosis
induction. This observation is in line with the accumulation of
high levels of MLKL without cell death induction as long as the
ESCRT system is operating38, 39.
MLKL is active in the nucleus. Our data suggest that RIPK3
kinase is phosphorylated, i.e., active in the nucleus. Therefore,
MLKL as a substrate of RIPK3 could also be phosphorylated in
the nucleus. Indeed, we detected phosphorylated MLKL (phos-
pho-MLKL) in the nucleus-enriched fractions of FADD-deficient
Jurkat cells after 3 h of TNF treatment when MLKL levels in the
cytosolic and nucleus-enriched fractions were equalized by
loading four times more nucleus-enriched fraction (Fig. 4a). At
this time point, nuclear RIPK1 was ubiquitinated but cells were
not positive for SYTOX Green (Fig. 2f, h; Supplementary Fig. 1).
After 6 h of TNF treatment, SYTOX green-positive cells were
detected (Supplementary Fig. 1). To provide further evidence that
RIPK3 may phosphorylate MLKL in the nucleus, kinase-dead
wild type or the corresponding NLS-tagged RIPK3 variant were
expressed in HeLa cells and the phosphorylation status of
endogenous MLKL was determined (Fig. 4b). Phospho-MLKL
was observed in nuclear extracts only when HeLa cells expressed
wild type or NLS-RIPK3, but not the corresponding kinase-dead
mutants (Fig. 4b). Furthermore, the intensity of the p-MLKL
band was increased when cells expressed NLS-RIPK3 compared
to wild-type RIPK3 (Fig. 4b), likely due to enhancement of the
pro-death activity of NLS-RIPK3 (Fig. 1g). These results confirm
that RIPK3 phosphorylates MLKL in the nucleus.
However, it was previously suggested that phosphorylation of
MLKL is needed for nuclear import21. To investigate if initial
phosphorylation of MLKL in the cytosol dictates its import into the
nucleus, we analyzed the nucleo-cytoplasmic shuttling of phospho-
deficient and phospho-mimetic MLKL mutants (T357A/S358A
and T357E/S358D, respectively). In the absence of LMB, phospho-
deficient MLKL was retained in the nucleus more than wild-type
MLKL or phospho-mimetic MLKL, indicating that phosphoryla-
tion of MLKL is required for its export rather than its import
(Fig. 4c, d). Moreover, when LMB was co-expressed with wild-type
RIPK3, it led to similar nuclear retentions: 22± 4.8% of phospho-
mimetic MLKL, 24± 11.2% of phospho-deficient MLKL, and 17±
2.6% of wild-type MLKL (Fig. 4c). Hence, phosphorylation of
MLKL and its associated conformational change might not be
required for its nuclear import.
It has been reported that following its phosphorylation, MLKL
assembles into disulfide-linked, SDS-stable oligomers6, 40. Follow-
ing TNF treatment, a band running at the height of putative
trimeric MLKL was observed in nuclear extracts (Fig. 4e). The
integrity of these disulfide-linked lower-order MLKL oligomers
(e.g., trimers or tetramers) was ensured by their absence under
reducing conditions. This result is in agreement with the
described sequence of events during MLKL activation19, namely,
the detection of p-MLKL associated with the appearance of lower-
order MLKL oligomers (Fig. 4a). Together, our results are
consistent with the presence of phosphorylated RIPK3 and the
phosphorylation and oligomerization of MLKL in the nucleus
during TNF-induced necroptosis.
Nuclear active RIPK3 and MLKL oligomerize in the cytosol.
Following necroptosis induction, RIPK3 forms amyloid-like
platforms, which are seen as cytosolic dots and are associated
with necrosome formation11, 19, 41. We confirmed that over-
expressed GFP-RIPK3 formed discrete dots in the cytosol of HeLa
cells treated with TBZ19 (Fig. 5a); the spots were not evident
under apoptotic conditions (TNF and BV6). Considering the
appearance of nuclear, lower order MLKL oligomers during
necroptosis (Fig. 4e), we hypothesized that MLKL might exit the
nucleus complexed with RIPK3 to nucleate the formation of
higher order oligomers in the cytosol. If so, the observed cytosolic
GFP-RIPK3 dots would also contain MLKL. Accordingly, after
co-expression of MLKL-GFP and mCherry-RIPK3 at toxic levels,
both RIPK3 and MLKL localized in cytosolic dot-like structures
(Fig. 5b). Besides this particular fluorescence pattern, cells with-
out obvious cytosolic MLKL-GFP dots were also evident. In these
cells, MLKL-GFP was present in a ring-like pattern at the cell
periphery while mCherry-RIPK3 was still detectable as cytosolic
dots (Fig. 5b). This staining could represent MLKL recruited to
the plasma membrane to participate in membrane permeabili-
zation and hence, would characterize cells further downstream in
the necroptotic signaling pathway6. Further evidence for the
requirement of MLKL in the formation of cytosolic GFP-RIPK3
dots was provided by the absence of such dots when MLKL was
knocked down (Fig. 5c). Instead, GFP-RIPK3 was present as a
diffuse pattern in the cytosol and the nucleus, indicating
impairment of its export from the nucleus. Importantly, expres-
sion levels of RIPK3 were comparable between control siRNA and
MLKL siRNA transfections (Supplementary Fig. 8). Thus, MLKL
appears to mediate the nuclear export of RIPK3 and to promote
cytosolic formation of higher order RIPK3 platforms. Since our
data suggest that phospho-RIPK3 and phospho-MLKL are
formed in the nucleus and subsequently exported cooperatively to
assemble into higher order complexes in the cytosol, cytosolic
RIPK3:MLKL dots should contain phospho-RIPK3 and phospho-
MLKL. Indeed, immunostainings of phospho-RIPK3 and endo-
genous phospho-MLKL in HeLa cells expressing GFP-RIPK3 and
treated with TBZ revealed cytosolic dots co-localized with GFP-
RIPK3 cytosolic dots (Fig. 5d, e). To validate these results on
endogenous levels in MEF cells, we tested the available anti-
mouse phospho-RIPK3 and anti-mouse phospho-MLKL anti-
bodies on these cells (Supplementary Fig. 9). However, though the
immunostaining patterns were likely specific, they were not suf-
ficiently over the threshold of background fluorescence, pre-
venting interpretation of the results.
Inhibition of nuclear export machinery by LMB led to an
increase in nuclear retention from 13± 3.2% to 37± 3.9% of total
cellular GFP-RIPK3 (Fig. 5g). Likewise, inhibition of nuclear
import by GppNHp led to nuclear retention of 31± 7.6% of total
cellular GFP-RIPK3. In both conditions, TBZ-induced cytosolic
GFP-RIPK3 dots were not induced (Fig. 5f, g). Moreover, no
cytosolic p-RIPK3 dots were seen when nuclear export was
inhibited by LMB. Instead, a diffuse human phospho-RIPK3
immunostaining was visible in the nucleus (Fig. 5h). As GppNHp
did not inhibit nuclear import of RIPK3 but affected its export,
we speculate that GppNHp leads to retention of phospho-RIPK3
in the nucleus. Consequently, GppNHp treatment would result in
retention of phospho-RIPK3 in the nucleus, giving a phospho-
RIPK3 immunostaining comparable to the one observed follow-
ing LMB treatment. Analysis of the intracellular distribution of
endogenous human phospho-MLKL in the presence of TBZ +
LMB showed that no cytosolic p-MLKL dots were present.
However, a nuclear diffuse human phospho-MLKL immunos-
taining was not detected: the immunofluorescence signal might
have been below the detection limit and not over the threshold of
background fluorescence (Supplementary Fig. 10). These results
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show that nuclear export is important for the formation of
phospho-MLKL dots in the cytosol. Taken together, these data
strongly suggest that RIPK3 phosphorylates MLKL in the nucleus
and then they are cooperatively exported to the cytosol, where
phospho-RIPK3 and phospho-MLKL form higher order func-
tional platforms in the cytosol.
Discussion
The effector molecule of necroptosis, MLKL, is activated on a
RIPK3-containing signaling platform, the cytosolic necrosome.
This has been visualized by confocal imaging and was described
as the formation of cytosolic RIPK3 dots11, 19, 41. Here we show
that formation of cytosolic RIPK3 dots apparently depends on the
export of RIPK3 and MLKL from the nucleus (Fig. 6). In the
nucleus, RIPK3 and MLKL are phosphorylated and oligomerized.
Thus, the joint nuclear export of phospho-RIPK3 and phospho-
MLKL to the cytosol is necessary for nucleation of the necrosome
in the cytosol and subsequent cell death. However, the extent to
which nuclear passage is important for necroptosis induction is
unknown. Our finding that LMB and GppNHp reduce necrop-
tosis only by half (Fig. 1) may reflect the redundancy and
adaptability of biological systems, which produce partial effects










































































































Fig. 4 MLKL is active in the nucleus. a Immunoblot of phospho-MLKL (p-MLKL) showing comparison of MLKL levels in nuclear and cytosolic fractions of
TNF-treated FADD-deficient Jurkat cells. MLKL levels were equalized between nuclear and cytosolic fractions by loading four times more of the nucleus-
enriched fraction. b Immunoblot of p-MLKL showing comparison of MLKL levels in nucleus-enriched and cytosolic fractions of HeLa cells expressing
untagged-RIPK3, NLS-RIPK3, or the corresponding kinase-dead mutants. c Confocal images of single-optical sections of HeLa cells transiently expressing
MLKL-GFP, phosphodeficient (T357A/S358A) MLKL-GFP or phosphomimetic (T357E/S358D) MLKL-GFP, and Flag-RIPK3. Scale bars: 10 µm.
d Quantification of the percentage of nuclear MLKL-GFP, phosphodeficient (T357A/S358A) MLKL-GFP or phosphomimetic (T357E/S358D) MLKL-GFP
transiently transfected in HeLa cells, which also co-expressed Flag-RIPK3 and were treated or untreated with LMB. For wild-type MLKL 8 (LMB untreated)
and 9 (LMB treated) transfected cells were analyzed; for phosphodeficient MLKL 12 (for both LMB untreated or treated) transfected cells and for
phosphomimetic MLKL 8 (LMB untreated) and 9 (LMB treated) transfected cells were analyzed. n= 1. Plots indicate averages± S.E.M. e Immunoblot of
MLKL under non-reducing and reducing conditions of nucleus-enriched fraction from FADD-deficient Jurkat cells treated with TNF for the indicated times
and the redox catalyst copper(II)(1,10-phenanthroline)3 (CuPhe). All immunoblots are representative of two or three independent experiments. Uncropped
images of Western blots are shown in Supplementary Fig. 17
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nuclear passage and activation of RIPK3 and MLKL is a partial
amplifying mechanism enhancing and accelerating necroptosis
execution.
Following TNF-mediated induction of necroptosis, RIPK1 was
reported to be ubiquitinated within the RIPK1–RIPK3 necrosome35,
36. We detected ubiquitinated RIPK1 in the nucleus (Fig. 2), sug-
gesting that a protein complex containing RIPK1–RIPK3 formed in
the nucleus promotes the activation of RIPK3 kinase activity in the
nucleus. In support of this hypothesis, we showed that the kinase
activity of RIPK3 was not required for its nuclear import (Fig. 3a)
and that RIPK3 is phosphorylated and hence activated in the
nucleus (Fig. 3c). Following its activation, RIPK3 phosphorylates
MLKL, which leads to its oligomerization. In accordance with
the nuclear localization of active RIPK3, we also detected its pro-
totype substrate, MLKL, and the consequent formation of
MLKL-containing lower-order oligomers in the nucleus (Fig. 4a, e).
Like RIPK3, MLKL phosphorylation is not necessary for its import
(Fig. 4c), indicating that these phosphorylation-dependent activation
events happen in the nucleus.
Kinases release their substrates after phosphorylating them.
However, in RIPK3-mediated phosphorylation of MLKL, a pro-
nounced conformational change induced in MLKL results in the
release of its 4HBD9 and in helix α6 mediated oligomerization42.
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between the kinase domain of RIPK3 and the pseudokinase
domain of MLKL, which leads to formation of a phospho-RIPK3:
phospho-MLKL complex43. Such a complex might be exported
from the nucleus in a cooperative manner (Fig. 3e, 5c, f), resulting
in further nucleation of cytosolic necrosome complexes by RIPK3
amyloid-like platform formation43. In that scenario, the nuclear
export of phospho-RIPK3 is needed to promote cytosolic phos-
pho-RIPK3:phospho-MLKL oligomerization (Fig. 5h).
The assembly of higher order signaling platforms, such as the
necrosome is commonly seeded by polymerization of pre-formed
subunits (protomers). Thus, the observed nuclear lower-order
MLKL oligomers (Fig. 4e) may represent a p-RIPK3:p-MLKL
hetero-oligomer that functions as the protomer for the cytosolic
formation of higher order p-RIPK3:p-MLKL oligomers (Fig. 6).
In contrast to our hypothesis, previous work by Sun et al.19
showed that inhibition of MLKL did not interfere with the for-
mation of RIPK3 dots. However, we point out that Sun et al.19
showed the effect of NSA treatment on the distribution of GFP-
RIPK3 following MLKL knockdown in HeLa cells. Our results
demonstrate that NSA is autofluorescent and leaks in the FITC
(green) channel (Supplementary Fig. 11), and so it should not be
included in fluorescence microscopy based on green fluorescence.
Similar issues in the results reported by Sun et al. may have
contributed to differences in data interpretation.
According to current knowledge of necroptotic signaling, the
pseudokinase MLKL is activated by RIPK3-dependent phos-
phorylation of its pseudokinase domain, which causes a con-
formational change that exposes the membrane-permeabilizing
4HBD9. We observed that MLKL was also phosphorylated in the
nucleus, suggesting that its phosphorylation occurs upstream of
cytosolic necrosome formation (Fig. 4). However, phosphoryla-
tion and oligomerization of MLKL in the nucleus apparently did
not lead to execution of its effector function (membrane per-
meabilization) because the nuclear envelope was apparently not
disintegrated (Fig. 5a). In this respect, nuclear phosphorylated
MLKL could fulfill a canonical pseudokinase function by acting as
an allosteric activator of RIPK3 in order to promote correct
protomer formation44.
The subsequent cytosolic assembly of phospho-RIPK3:phos-
pho-MLKL protomers into higher order signaling complexes
would increase the local concentration of phospho-MLKL, pos-
sibly allowing proximity-driven conformational rearrangements
and/or additional phosphorylation of MLKL, which have been
shown to tune MLKL activation44. Consequently, MLKL would
be further activated on the scaffold of cytosolic phospho-RIPK3:
phospho-MLKL oligomers, resulting in MLKL translocation and
recruitment to the plasma membrane and consequent membrane
permeabilization6–10, 45.
There is a recent description of the accumulation of p-MLKL,
active RIPK3 and active RIPK1 in the nucleus before the onset of
necroptosis or induction of the NLRP3 inflammasome21.
Considering that MLKL can cell-intrinsically trigger the NLRP3
inflammasome46, those findings could point to an early nuclear
checkpoint where the decision between inflammation and
necroptosis induction is made. By using nuclear import and
export inhibitors combined with genetic approaches, we identi-
fied a nuclear checkpoint, further downstream in the necroptotic
signaling pathway, which controls the formation of the cytosolic
necrosome and consequently induction of cell death. Moreover,
the observations of Yoon et al.21 and our study show that the
necroptotic signaling pathway does not represent a simple com-
plex I to II transition in the cytosol, but involves compartmen-
talization of key necroptotic players into the nucleus.
As a platform, RIPK3 sits in control of both necroptotic and
apoptotic complexes15–17, 24, whereas active RIPK3 kinase is
required for necroptosis but not apoptosis47, 48. Our results
provide evidence that RIPK3 kinase is active in the nucleus
during necroptosis, implying that a RIPK3-activating complex is
assembled in the nucleus (Figs. 2, 4). This compartmentalization
in the nucleus provides a spatial separation from apoptotic sig-
naling complexes, which are formed in the cytosol2. Thus, it may
not be the level of respective downstream effectors that deter-
mines an apoptotic or necroptotic signaling outcome, as sug-
gested by Cook et al.15, but rather the intracellular localization of
RIPK3-containing death complexes. Although many questions
remain about this nuclear checkpoint in necroptotic signaling, the
compartmentalization of key necroptotic signaling events in the
nucleus could be a mechanism that ensures correct interpretation
of necroptotic vs. apoptotic death signals.
Methods
Constructs. The sequences encoding wild-type human RIPK1, human RIPK3, and
human MLKL were cloned in pENTR3C using the CloneEZ PCR Cloning Kit
(GenScript). The NLS sequence of SV40 large T was N-terminally fused to the
coding sequence. Next, these sequences were transferred into homemade, modified
pCDNA 3.1 vector backbones (vector map, Supplementary Fig. 12) using the LR
Gateway recombination system (Life Technologies) resulting in N-terminally tag-
ged RIPK3 with flag (FLAG-RIPK3) or EGFP-RIPK3 (GFP-RIPK3), and C-
terminally tagged MLKL with EGFP (MLKL-EGFP). For mCherry-RIPK3, the
EGFP gene of pDest-EGFP-hRIPK3FL was replaced by the mCherry cassette of
pmCherry-C1 (Clontech) using the CloneEZ PCR Cloning Kit (GenScript). RIPK3
RHIM (Addgene ID 41385) and D160N (Addgene ID 41386) were purchased from
Addgene and the coding sequence was cloned in pENTR3C. RIPK3 K50A was
generated by QuickChange mutagenesis (Agilent Genomics) of GFP-NLS-RIPK3
and GFP-RIPK3. MLKL-GFP (T357A/S358A) and MLKL-GFP (T357E/S358D)
were generated by by QuickChange mutagenesis (Agilent Genomics) of MLKL—
GFP. All generated plasmids have been deposited at the plasmid collection of the
Belgian Coordinated Collections of Microorganisms (BCCM) (http://bccm.belspo.
be/catalogues/lmbp-plasmids-catalogue-search).
Cell lines and treatments. FADD-deficient Jurkat T cells (purchased from ATCC)
were cultured in Roswell Park Memorial Institute (RPMI). HeLa cells (ECACC) and
SV40 large T-immortalized MEF cells (generated in house) were cultured in Dul-
becco’s modified eagle’s minimal essential medium. Both media were supplemented
with 10% fetal calf serum (FCS) and L-glutamine (200mM). Cell cultures were
routinely tested for mycoplasma contamination. HeLa cells were transfected using
Fig. 5 LMB and GppNHp prevent oligomerization of cytosolic RIPK3:MLKL. a Confocal imaging of single-optical sections of HeLa cells transiently
expressing GFP-RIPK3 treated with TBZ (TNF, BV6, and zVAD.fmk) or TB (TNF and BV6). b Confocal imaging of single-optical sections of HeLa cells
transiently expressing mCherry-RIPK3 and MLKL-GFP. Shown are merged images of mCherry-RIPK3, MLKL-GFP and Hoechst; inset is magnified.
c Confocal images of single-optical sections of HeLa cells transiently expressing GFP-RIPK3 and transfected with control (con) siRNA or MLKL siRNA and
treated with TBZ. Representative images of two independent experiments are shown. d Confocal images of single-optical sections of HeLa cells transiently
expressing GFP-RIPK3, TBZ treated or untreated followed by anti-human p-RIPK3 immunostaining. Representative images of two independent experiments
are shown. e Confocal images of single-optical sections of HeLa cells transiently expressing GFP-RIPK3, TBZ treated or untreated followed by anti-human
p-MLKL immunostaining. Inset is magnified. Representative images of three independent experiments are shown. f Confocal images of single-optical
sections of HeLa cells transiently expressing GFP-RIPK3, treated with TBZ, TBZ + GppNHp or TBZ + LMB. Representative images of two independent
experiments are shown. g Quantification of the percentage of nuclear GFP-RIPK3 transiently expressed in HeLa cells treated with TBZ, TBZ + GppNHp, and
TBZ + LMB (10–40 transfected cells were analyzed of n= 2). Plots indicate averages± S.E.M. h Confocal images of single-optical sections of HeLa cells
transiently transfected with control vector or GFP-RIPK3, treated with TBZ + LMB, and immunostained with an anti-human p-RIPK3 antibody.
Representative images of two independent experiments are shown. Scale bars in all images: 10 µm
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JetPrime reagent (Polyplus transfection) according to manufacturer’s instructions.
After 24 h, the cells were pre-treated for 30min with 20 μM z-Val-Ala-DL-Asp
(Ome)-fluoromethylketone (zVAD-fmk) (Bachem AG), and 2 μM BV6 (Selleck) or
10 μM TGF-β-activated kinase 1 inhibitor (TAKi) (AnalytiCon Discovery GmbH),
followed by treatment with human TNF (600 lU/ml). Ten micromolar Necrostatin-1
(Nec-1) (Calbiochem, Merck) and 10 μM Necrosulfonamide (NSA) (Toronto
Research chemicals) were included in the pre-treatment. Leptomycin B (LMB)
(Sigma-Aldrich) was used at a concentration of 1 μM for Hela cells and 0.25 μM for
FADD-deficient Jurkat cells and was added at the time of transfection or 1 h before
TNF treatment or confocal imaging. GppNHp (non-hydrolyzable GTP analog,
Sigma-Aldrich) was added at 1 mM 2 h before treatment or confocal imaging.
Subcellular fractionation. Nucleus-enriched fractions of FADD-deficient Jurkat
cells were obtained as described49. Briefly, cells were swollen in hypotonic buffer and
ruptured by dounce homogenization. After clearing lysates at 100×g for 5 min,
nucleus-enriched fractions were pelleted at 1300×g for 10min. Cytosolic fractions
were obtained by centrifugation of the supernatants at 17,000×g for 10min. Nuclear
extracts of HeLa cells were obtained as described50. Briefly, cells were swollen in
hypotonic buffer, followed by fractional lysis in NP-40. After differential spinning,
nucleus-enriched fractions and cytosolic fractions were collected. To compare
posttranslational modifications of cytosolic and nuclear RIPK1 and MLKL, protein
levels were equalized between nucleus-enriched and cytosolic fractions by loading
four times more of the nucleus-enriched fraction than the cytosolic fraction.
Cell death measurement. HeLa cells transfected with GFP-fused constructs were
collected and left to recover before staining with SYTOX Blue (Life Technologies) at
a final concentration of 5 μM. Cell death in the GFP-positive cell population was
determined by analyzing SYTOX Blue positive cells on a FACSVerse flow cytometer
(BD Biosciences) and by using FlowJo software (gating strategy see Supplementary
Fig. 13). Jurkat cells were stained with 5 μM SYTOX Green (Life Technologies) and
analyzed by using a FLUOstar Omega fluorescence plate reader (BMG Labtech
GmbH, Ortenberg, Germany). Percent cell death was calculated as follows:
100 ´ induced fluorescence background fluorescenceð Þ½ 
 maximal fluorescence achieved by TritonX100ð
permeabilization background fluorescenceÞ:
The data are presented as mean± S.E.M of at least 2–3 independent
experiments. All cell death profiles in this paper are shown as averages± S.E.M. A
comparison of groups was performed using paired, two-sided Student’s t-test
assuming normal distribution. A value of p< 0.05 was considered to indicate
statistical significance.
Antibodies. The following antibodies were used for Western blotting or immu-
nostainings: anti-FLAG-HRP (Sigma-Aldrich; Cat. No. A8592, Lot. No. 116K6031),
anti-RIPK1 (BD Bioscience, Cat. No. 610459), anti-RIPK3 (Abcam, Cat. No.
ab56164), anti-MLKL (Genetex, Cat. No. GTX107538, Lot. No. LN40030), anti-p-
MLKL (Abcam; Cat. No. 187091; Lot No. GR12667-11), anti-Histone (Santa Cruz;
Cat. No. sc-8030, Lot No. L0808), anti-LDHA (Cell Signaling; Cat. No. 2012, Lot
No. LN002), anti-Flotillin (Cell Signaling; Cat. No. 3253 S, Lot No. 10/2013), anti-
tubulin-HRP (Abcam; Cat. No. ab21058, Lot. GR260583-2). For immunostainings,
the following antibodies were used: anti-p-hMLKL S358 (Abcam; Cat. No.
ab187091; Lot No. GR12667-11); anti-p-mMLKL S345 (Abcam; Cat. No. ab196436;
Lot No. GR246882-1); anti-p-hRIPK3 S227 (Abcam; Cat. No. ab209384; Lot No.
GR257915-8); anti-p-mRIPK3 T231 + S232 (Abcam; Cat. No. ab205421; Lot No.
GR268165-4) or S232 (Abcam; Cat. no 195117; Lot No. GR268165-4). Full scans of
all Western blots presented in figures or Supplementary Figures are shown in
Supplementary Figs. 14–18.
Intracellular localization by confocal microscopy. HeLa cells were transfected
with GFP-tagged RIPK3 or a combination of mCherry-RIPK3 and MLKL-GFP
constructs using Jetprime transfection (Polyplus Transfection) according to manu-
facturer’s protocol. After 16 h, the cells were treated with TBZ and nuclei were
counterstained with Hoechst. The cells were either fixed with 1% PFA or left unfixed.
For immunostaining, transiently transfected HeLa cells were fixed with 1% PFA,
permeabilized in 0.1% Triton, and blocked with 0.2% donkey serum in PBT buffer
(PBS + 0.1% Tween 20). The cells were then incubated overnight with the indicated
antibodies followed by incubation with DyeLight 568 conjugated secondary antibodies
for 1 h. Nuclei were stained with Hoechst. Cells were imaged by confocal microscopy
using an LSM780 or LSM880 confocal microscope (Zeiss) and the observer was
blinded to the identities of specimens. Images (8 bit) were acquired with a Plan-
Apochromat 63X/1.4 oil objective at a resolution of 1528 by 1528 pixels (pixel size 70
nm× 70 nm). The microscope is equipped with a Ti:Sa laser (MaiTai DeepSee,
SpectraPhysics) to image Hoechst and an Ar laser to excite GFP. The scanhead
contains 2 PMTs and a QUASAR detection unit. Images were processed using Fiji
imaging software. For quantification, cells were imaged using a spinning disk confocal
microscope (Zeiss) equipped with a Rolera EMCCD camera. A Plan-Apochromat
40X/1.4 Oil DIC (UV) VIS-IR M27 objective was used. Pixel sizes were 0.167 by 0.167
μm and z-step size 0.240 μm. EGFP was excited by a 488-nm diode laser and Hoechst
by a 405-nm diode laser. Quantification of nuclear and cytosolic fractions was done
using Volocity 3D Image Analysis Software (PerkinElmer, UK). By means of 3D
segmentation, the volume of total protein and the volume of protein in the nucleus
were determined for each cell to calculate the nuclear fraction of the protein in each
cell. For each condition, 7–9 fields of view were randomly selected and imaged. Cells
within these fields were analyzed, resulting in 12–60 data points per condition. All
quantitative datasets in this publication are presented as aveages± S.E.M.
MLKL oligomerization. Formation of MLKL oligomers was previously analyzed by
the cysteine crosslinker Bismaleimidohexane (BMH), which chemically joins two or
more molecules by a covalent disulfide bond45. We analyzed the formation of MLKL
oligomers by using the redox catalyst CuPhe (20mM 1,10 phenanthroline with 300
mM CuSO4)51. Like BMH, copper (II)(1,10-phenanthroline)3 (CuPhe) induces the
formation of disulfide bonds, but it is more efficient. The oxidation with CuPhe
yielded disulfide-linked MLKL containing low-molecular weight complexes.
Nucleus-enriched fractions isolated form control- and TNF-treated FADD-deficient
Jurkat cells were incubated with CuPhe for 30min on ice. The reaction was then
quenched by incubation with 100mM EDTA for 15min. Oligomerization of MLKL












































Fig. 6 Nuclear RIPK3 and MLKL contribute to cytosolic RIPK3:MLKL oligomerization during necroptosis. Hypothetical model of the nuclear events following
necroptosis induction. Nuclear RIPK1 is ubiquitinated to provide a scaffold for nuclear RIPK3 kinase activation. After its phosphorylation, RIPK3 associates
with MLKL, leading to phosphorylation of MLKL. p-RIPK3 and p-MLKL are then cooperatively exported from the nucleus to contribute to cytosolic
necrosome formation and consequently to cell death
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Immunoprecipitation. Nucleus-enriched fractions were lysed in 6 M urea. Before
immunoprecipitation using protein A-pre-coupled anti-ubiquitin Dynabeads
(Invitrogen), lysates were diluted to 0.2 M urea with lysis buffer (20 mM Tris-HCl,
pH 7.4, 135 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% NP-40).
After overnight incubation, beads were washed in lysis buffer and immunopreci-
pitates were eluted in Laemmli buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10%
glycerol). Immunoprecipitates were analyzed by immunoblotting.
RNA interference. Control and MLKL siRNA ON-TARGET SMARTpools were
obtained from Dharmacon. HeLa cells were transfected with the siRNAs using
Interferin (Polyplus Transfection) according to manufacturer’s instructions.
Data availability. All the relevant data that are not in the article or Supplementary
Files are available from the authors upon request. Plasmid constructs generated for
this study have been deposited at the plasmid collection of the Belgian Coordinated
Collections of Microorganisms (BCCM). LMPB codes or Addgene ID’s are pro-
vided in Supplementary Data 1.
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